MNA
BBIO icon

Manning & Napier Advisors’s BridgeBio Pharma BBIO Stock Holding History

Manning & Napier Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09K Buy
+29
New +$2.03K ﹤0.01% 739

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Manning & Napier Advisors's BBIO Position: Q2 2026 in Review

Manning & Napier Advisors opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 29 shares worth $2.09K. The stake represents ﹤0.01% of the portfolio and ranks #739 among its holdings.

474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Manning & Napier Advisors held 29 shares of BridgeBio Pharma worth $2.09K as of Q2 2026.
  • BridgeBio Pharma was a new Manning & Napier Advisors position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #739 holding.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.